{
    "brief_title": "A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin",
    "phase": "Phase 2; Phase 3",
    "drugs": "['lapatinib/herceptin']",
    "drugs_list": [
        "lapatinib/herceptin"
    ],
    "diseases": "['HER2-positive Breast Cancer']",
    "diseases_list": [
        "HER2-positive Breast Cancer"
    ],
    "enrollment": "482.0",
    "inclusion_criteria": "inclusion criteria: \n\n the first diagnosis of invasive breast cancer, confirmed by histology or cytology, and surgical resection of the primary lesions before receiving any anti breast cancer treatment; \n\n female patients, aged 18 years and less than 80 years of age; \n\n surgical resection of the primary tumor pathological examination, showed HER2 positive (defined as immunohistochemistry [IHC] 3+ or fluorescence in situ hybridization (FISH) positive); \n\n hormone receptor status is known, lymph node positive or sentinel lymph node negative but high risk factors \n\n the eastern oncology cooperative group (ECOG) patients with physical status score was 0 -2; \n\n baseline LVEF >50% \n\n the relevant institutional review board (IRB) or independent ethics committee (IEC) written informed consent \n\n ",
    "exclusion_criteria": ": \n\n the subjects in pregnancy or lactation; \n\n pregnant women may be within the first 7 days before pregnancy test positive (urine or serum). \n\n received chemotherapy, endocrine or anti HER2 anti-tumor therapy; \n\n congestive heart failure, unstable angina, heart failure or myocardial infarction and other diseases; \n\n other invasive tumors (including the second primary breast cancer), may affect the outcome of the evaluation and program compliance; but the treatment of patients with disease free survival at least more than 5 years can be selected; \n\n with chronic liver disease in patients with liver dysfunction and / or with clinical manifestations: the serum total bilirubin > 2.5 * ULN; or INR = 1.5 but no bilirubin. serum ALT or AST> * 3 * ULN; alkaline phosphatase >2.5 * ULN; ALT or AST can be gradually increased, but with gradually increasing fatigue, nausea and vomiting, fever, right upper quadrant pain or tenderness \n\n hematopoietic dysfunction, defined as follows: neutrophil count (ANC) <1.5 * 109/L; platelet <100 * 109/L; hemoglobin <9 g/dL; \n\n other serious diseases, including: congestive heart failure (heart function NYHA grade II, III, IV) or occurred within 6 months of congestive heart failure, unstable angina, arrhythmia, myocardial infarction patients can't control or other severe cardiovascular disease; breathing at rest or need oxygen therapy; serious infection; uncontrolled diabetes; \n\n there is a serious psychological or mental abnormalities, estimated that the participants to participate in this study is not strong; \n\n known to study drug allergy; \n\n the past 30 days participated in the study of other drug clinical trials. \n\n 1, failed to complete the clinical trial of at least 1 cycles according to the program, can not carry out safety and efficacy evaluation 2, a serious violation of this research program, not in accordance with the prescribed dose, method and course of medication. \n\n Patients will receive lapatinib treatment, until a predetermined end end point, or development of unacceptable toxicity, or withdrawal of consent, or illness or death, to appear before the subject.",
    "brief_summary": "This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline",
    "NCT_ID": "NCT03085368"
}